Literature DB >> 2565176

Clinical pharmacokinetics of non-opiate abused drugs.

U Busto1, R Bendayan, E M Sellers.   

Abstract

The present review discusses the available data on the kinetic properties of non-opiate abused drugs including psychomotor stimulants, hallucinogens and CNS-depressants. Some of the drugs of abuse reviewed here are illicit drugs (e.g. cannabis, cocaine), while others are effective pharmacological agents but have the potential to be abused (e.g. benzodiazepines). Although some of the drugs mentioned in this review have been in use for centuries (e.g. caffeine, nicotine, cocaine, cannabis), knowledge of their kinetics and metabolism is very recent and in some cases still incomplete. This is partially due to the difficulties inherent in studying drugs of abuse in humans, and to the complex metabolism of some of these drugs (e.g. cannabis, caffeine) which has made it difficult to develop sensitive assays to determine biological pathways. Although drugs of abuse may have entirely different intrinsic pharmacological effects, the kinetic properties of such drugs are factors contributing to abuse and dependence. The pharmacokinetic properties that presumably contribute to self-administration and drug abuse include rapid delivery of the drug into the central nervous system and high free drug clearance. Kinetic characteristics also play an important role in the development of physical dependence and on the appearance of a withdrawal syndrome: the longer the half-life, the greater the likelihood of the development of physical dependence; the shorter the half-life, the earlier and more severe the withdrawal. The balance between these 2 factors, which has not yet been carefully studied, will also influence abuse patterns. The clinical significance of kinetic characteristics with respect to abuse is discussed where possible.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2565176     DOI: 10.2165/00003088-198916010-00001

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  178 in total

1.  Amphetamine metabolism in amphetamine psychosis.

Authors:  E Anggård; L E Jönsson; A L Hogmark; L M Gunne
Journal:  Clin Pharmacol Ther       Date:  1973 Sep-Oct       Impact factor: 6.875

2.  Correlation of brain levels of drugs with behavioral effects.

Authors:  R P Maickel; R H Cox; F P Miller; D S Segal; R W Russell
Journal:  J Pharmacol Exp Ther       Date:  1969-02       Impact factor: 4.030

3.  Prolonged absorption with development of tolerance to toxic effects after cutaneous exposure to nicotine.

Authors:  N L Benowitz; T Lake; K H Keller; B L Lee
Journal:  Clin Pharmacol Ther       Date:  1987-07       Impact factor: 6.875

4.  [A microprocessor controlled infusion scheme for midazolam to achieve constant plasma levels (author's transl)].

Authors:  P M Lauven; H Stoeckel; H Schwilden
Journal:  Anaesthesist       Date:  1982-01       Impact factor: 1.041

5.  Pharmacodymamics and pharmacokinetics of diazepam in an abuser.

Authors:  M Linnoila; C W Erwin; A Brendle; T Skinner; P A Routledge
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1980-07

6.  Nicotine and cotinine concentrations in serum and urine of infants exposed via passive smoking or milk from smoking mothers.

Authors:  W Luck; H Nau
Journal:  J Pediatr       Date:  1985-11       Impact factor: 4.406

7.  Chlordiazepoxide and oxazepam disposition in cirrhosis.

Authors:  E M Sellers; D J Greenblatt; H G Giles; C A Naranjo; H Kaplan; S M MacLeod
Journal:  Clin Pharmacol Ther       Date:  1979-08       Impact factor: 6.875

8.  Plasma protein binding of phencyclidine.

Authors:  H G Giles; W A Corrigall; V Khouw; E M Sellers
Journal:  Clin Pharmacol Ther       Date:  1982-01       Impact factor: 6.875

9.  Comparison of effects of marihuana cigarettes to three different potencies.

Authors:  M Perez-Reyes; S Di Guiseppi; K H Davis; V H Schindler; C E Cook
Journal:  Clin Pharmacol Ther       Date:  1982-05       Impact factor: 6.875

Review 10.  Relative abuse liability of triazolam: experimental assessment in animals and humans.

Authors:  R R Griffiths; R J Lamb; N A Ator; J D Roache; J V Brady
Journal:  Neurosci Biobehav Rev       Date:  1985       Impact factor: 8.989

View more
  21 in total

Review 1.  The need for speed: an update on methamphetamine addiction.

Authors:  Alasdair M Barr; William J Panenka; G William MacEwan; Allen E Thornton; Donna J Lang; William G Honer; Tania Lecomte
Journal:  J Psychiatry Neurosci       Date:  2006-09       Impact factor: 6.186

Review 2.  Neurocognitive effects of methamphetamine: a critical review and meta-analysis.

Authors:  J Cobb Scott; Steven Paul Woods; Georg E Matt; Rachel A Meyer; Robert K Heaton; J Hampton Atkinson; Igor Grant
Journal:  Neuropsychol Rev       Date:  2007-09       Impact factor: 7.444

3.  A comparison of psychotic symptoms in subjects with methamphetamine versus cocaine dependence.

Authors:  Peter D Alexander; Kristina M Gicas; Taylor S Willi; Clara N Kim; Veronika Boyeva; Ric M Procyshyn; Geoff N Smith; Allen E Thornton; William J Panenka; Andrea A Jones; Fidel Vila-Rodriguez; Donna J Lang; G William MacEwan; William G Honer; Alasdair M Barr
Journal:  Psychopharmacology (Berl)       Date:  2017-02-11       Impact factor: 4.530

Review 4.  Pharmacokinetic and pharmacodynamic principles of illicit drug use and treatment of illicit drug users.

Authors:  D I Quinn; A Wodak; R O Day
Journal:  Clin Pharmacokinet       Date:  1997-11       Impact factor: 6.447

Review 5.  Neurotoxicology Syndromes Associated with Drugs of Abuse.

Authors:  Rachel A Caplan; Jonah P Zuflacht; Jed A Barash; Corey R Fehnel
Journal:  Neurol Clin       Date:  2020-11       Impact factor: 3.806

Review 6.  Ontogeny of hepatic and renal systemic clearance pathways in infants: part II.

Authors:  Jane Alcorn; Patrick J McNamara
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

7.  Analgesic effects of propyphenazone in comparison to its combination with caffeine.

Authors:  H G Kraetsch; T Hummel; J Lötsch; R Kussat; G Kobal
Journal:  Eur J Clin Pharmacol       Date:  1996       Impact factor: 2.953

Review 8.  Caffeine in tea Camellia sinensis--content, absorption, benefits and risks of consumption.

Authors:  A Gramza-Michałowska
Journal:  J Nutr Health Aging       Date:  2014       Impact factor: 4.075

9.  Coexistence of passive and proton antiporter-mediated processes in nicotine transport at the mouse blood-brain barrier.

Authors:  Salvatore Cisternino; Hélène Chapy; Pascal André; Maria Smirnova; Marcel Debray; Jean-Michel Scherrmann
Journal:  AAPS J       Date:  2012-12-05       Impact factor: 4.009

Review 10.  Clinical pharmacokinetics of amfetamine and related substances: monitoring in conventional and non-conventional matrices.

Authors:  Rafael de la Torre; Magí Farré; Mónica Navarro; Roberta Pacifici; Piergiorgio Zuccaro; Simona Pichini
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.